Xin Wang

Dr. Xin Wang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 July 2013 in Drug Research
Verified
Journal Article
Closed access
PDF file
XWXin Wang
Xin Wang
LSL. Song
L. Song
NLN. Li
N. Li
ZQZ. Qiu
Z. Qiu
SZS. Zhou
S. Zhou
XCXijing Chen
Xijing Chen
Lipusu is the first paclitaxel liposome preparation approved in the world and has been widely used in China for the treatment of ovary, breast and non-small cell lung cancer. In present study we evaluated the pharmacokinetic and tissue distribution characteristics of paclitaxel liposome in Sprague-Dawley rats and Beagle dogs. A rapid and simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed for the determination of paclitaxel in plasma and tissues. The plasma concentrations of paclitaxel in both rats and dogs initially declined steeply, followed by slow elimination after intravenous administration of Lipusu at 5 mg/kg and 1 mg/kg, respectively. The pharmacokinetic parameters calculated by a non-compartmental method in rats and dogs were as follows: AUC0–24: 3 566.5±1 366.1 and 443.2±165.7 μg · h/L, CL: 1.5±0.5 and 2.1±0.6 L/h/kg, Vd: 20.0±7.8 and 38.4±12.5 L/kg, t1/2: 9.3±2.9 and 14.1±6.9 h, respectively. Biodistribution results in rats showed that except for brain and testis, liposomal paclitaxel was extensively distributed into various tissues, especially highly in liver and spleen.

1 February 2013 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
ZQZhixia Qiu
Zhixia Qiu
NLNing Li
Ning Li
XWXin Wang
Xin Wang
FTFengjie Tian
Fengjie Tian
QLQi Liu
Qi Liu
XCXijing Chen
Xijing Chen

7 July 2016 in Xenobiotica
Verified
Journal Article
Closed access
XWXin Wang
Xin Wang
MZMei Zheng
Mei Zheng
JLJia Liu
Jia Liu
ZQZhou Qiao
Zhou Qiao
WLwenyuan liu
wenyuan liu
FFFeng Feng
Feng Feng
1. In this study, the stereoselective pharmacokinetics of rhynchophylline (RIN) and isorhynchophylline (IRN) in rat plasma were investigated using liquid chromatography–tandem mass spectrometry (LC–MS/MS). 2. A rapid, robust and sensitive LC–MS/MS method for simultaneous quantification of RIN and IRN in rat plasma was established and validated. Chromatographic separation was performed on a Poroshell 120 EC-C18 column under a gradient elution with methanol and water containing 0.01% ammonia as mobile phase. Calibration curve was linear over a concentration range of 1–2000 ng/mL for both epimers. 3. After intravenous administration, there was no apparent difference in pharmacokinetic parameters between two epimers. However, after oral administration, RIN showed remarkable higher plasma exposure than IRN. The bioavailability, Cmax and AUC0–t of RIN were about 9.2-fold, 6.4-fold and 9.1-fold higher than those of IRN at 10 mg/kg, and 7.8-fold, 4.3-fold and 7.7-fold at 20 mg/kg, respectively. Additionally, with dosage enhanced from 10 mg/kg to 20 mg/kg, the plasma concentrations of RIN or IRN increased significantly and the bioavailability enhanced about three times. 4. In conclusion, the results of this work demonstrated for the first time that the pharmacokinetics of RIN and IRN have stereoselectivity.

23 May 2025 in eClinicalMedicine
Verified
Journal Article
Open access
SLSuying Lu
Suying Lu
YQYi Que
Yi Que
DLDongyang Liu
Dongyang Liu
FSFeifei Sun
Feifei Sun
XYXueting Yao
Xueting Yao
YZYi-zhuo Zhang
Yi-zhuo Zhang
Anlotinib is a novel highly potent multitargeted tyrosine kinase inhibitor. However, the safety, recommended dosage, pharmacokinetics (PK) characteristics, and efficacy of anlotinib in paediatric patients have not been fully studied. We aimed to evaluate the safety, PK, and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas. This was an open-label, single-centre, single-arm, phase I study utilizing a “3 + 3” design. Participants were recruited at the Sun Yat-sen University Cancer Centre in China. Paediatric patients aged 5–18 years with a diagnosis of high-risk, relapsed, or refractory sarcomas were eligible for enrolment in this study. Anlotinib was administered orally once daily on a 2-week-on/1-week-off schedule. Treatment continued until disease progression, death, unacceptable toxicity, or withdrawal of consent for any reason. For patients receiving anlotinib as maintenance therapy, the maximum treatment duration was one year. The primary endpoint of phase Ia was the maximum tolerated dose (MTD) of anlotinib. The primary endpoint of phase Ib was the recommended phase II dose (RP2D) of anlotinib. Secondary endpoints included safety, PK, and efficacy. Efficacy endpoints, such as objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), were assessed at every 2 cycles for patients with measurable lesions until disease progression or intolerable toxicity. Patients with a complete response (CR) at baseline were assessed every 4 cycles until disease progression, or intolerable toxicity, or upon completion of one year of treatment. The primary analysis included all participants who received at least one dose of anlotinib, following the per protocol approach. The safety analysis included all participants who received at least one dose of anlotinib and were monitored for adverse events during the treatment period. This study is registered with ClinicalTrials.gov, NCT04659733. Between December 29, 2020, and September 7, 2022, 34 patients were enrolled for toxicity. Among them, 61.8% (21/34) patients were evaluable for efficacy, and 38.2% (13/34) received anlotinib as maintenance therapy. Two patients (5.9%) experienced dose-limiting toxicities, including grade 3 hematuria and grade 3 hand-foot syndrome. AEs were reported in all patients, with most being grade 1 or 2 in severity. The most common AEs of any grade were hypothyroidism (58.8%, 20/34), diarrhoea (41.2%, 14/34) and abdominal pain (38.2%, 13/34). No grade 4 or treatment-related deaths occurred. PK analysis indicated a significant correlation between abdominal pain and higher steady-state trough concentrations [OR 1.08 (95% CI: 1.01–1.17), P = 0.04] as well as AUCτ [OR 1.00 (95% CI: 1.00–1.01), P = 0.04]. The MTD and RP2D of anlotinib for paediatric patients (5–18 years) was 8 mg for those under 35 kg and 12 mg for those 35 kg or more. The ORR and DCR for evaluable patients were 0% (95% CI: 0%–0%) and 52.4% (95% CI: 29.1%–75.7%), respectively. The 2-year PFS and OS rates for patients who received anlotinib as maintenance therapy were 84.6% (95% CI: 51.2%–95.9%) and 92.3% (95% CI: 56.6%–98.9%), respectively. Anlotinib was well tolerated in paediatric patients. Our findings provide preliminary evidence of the efficacy of anlotinib as a maintenance therapy in paediatric patients with high risk, relapsed/refractory sarcoma who achieved a CR. Further investigation of anlotinib in larger, controlled studies is needed to determine its clinical utility. The 10.13039/501100012166 National Key Research and Development Program of China , the National Science and Technology Major Projects, the 10.13039/501100001809 National Natural Science Foundation of China , the Young Science and Technology Talent Support Program of Guangdong Precision Medicine Application Association, and Capital’s Funds for Health Improvement and Research.

1 January 2014 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SYShuoye Yang
Shuoye Yang
ATAmer Talbi
Amer Talbi
XWXin Wang
Xin Wang
HSHanlin Song
Hanlin Song
XCXijing Chen
Xijing Chen